A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Recruiting now

Conditions studied: Geographic Atrophy, Macular Degeneration

In brief

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.

Key facts

Study ID: NCT06779773
Run by: Astellas Pharma Global Development, Inc.
People needed: 500
Starts: 2025-01-22
Expected to finish: 2030-10-31
Last updated by the study team: 2026-08-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
Patient willingness to complete the patient reported outcome (PRO).

You may not qualify if…

Patients who have any contraindication or are not eligible for treatment with ACP, including the following:
Active ocular or peri-ocular infection in either eye
Active, suspected intraocular inflammation in either eye
Hypersensitive to ACP or to any ingredient in the formulation
Patients currently participating in an investigational program with interventions outside of routine clinical practice.
Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.
Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.

Where it is running

Retina Associates of Michigan — Grand Blanc, Michigan, United States (enrolling)
Retina Consultants of Minnesota PLLC — Saint Louis Park, Minnesota, United States (enrolling)
Retinal Consultants of AZ — Phoenix, Arizona, United States (enrolling)
Harvard Eye Associates — Laguna Hills, California, United States (enrolling)
University of California Irvine Medical Center — Orange, California, United States (enrolling)
Retina Macula Institute of Arizona — Scottsdale, Arizona, United States (enrolling)
Retinal Consultants Medical Group Inc — Sacramento, California, United States (enrolling)
Retina Macula Institute — Torrance, California, United States (enrolling)
Rocky Mountain Lions Eye Institute — Aurora, Colorado, United States (enrolling)
Retina Consultants of Southern Colorado — Colorado Springs, Colorado, United States (enrolling)
Colorado Retina Associates, PLLC — Lakewood, Colorado, United States (enrolling)
Coastal Eye Surgeons — Greenwich, Connecticut, United States (enrolling)
Retina Consultants of Southern CA — Redlands, California, United States (enrolling)
Advanced Retina Institute — Bonita Springs, Florida, United States (enrolling)
University of Miami — Coral Gables, Florida, United States (enrolling)
Retina Care Specialists — Palm Beach Gardens, Florida, United States (enrolling)
Eye Physicians of Pinellas PA dba Eye Institute of West Florida — Tampa, Florida, United States (enrolling)
Retina Specialists of Tampa — Wesley Chapel, Florida, United States (enrolling)
Southeast Retina Center, P.C. — Augusta, Georgia, United States (enrolling)
University Retina and Macula Associates, P.C. — Oak Forest, Illinois, United States (enrolling)
Illinois Retina Associates — Oak Park, Illinois, United States (enrolling)
Illinois Eye Center — Peoria, Illinois, United States (enrolling)
Wolfe Eye Clinic — West Des Moines, Iowa, United States (enrolling)
Cumberland Valley Retina Consultants,P.C. — Hagerstown, Maryland, United States (enrolling)
Mississippi Retina Associates — Madison, Mississippi, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.